This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Evoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Evoke Pharma, Inc. (EVOK) delivered earnings and revenue surprises of -125.00% and -98.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Evoke Pharma (EVOK) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Evoke Pharma (EVOK) stock based on the movements in the options market lately.
New Strong Sell Stocks for August 24th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance
by Zacks Equity Research
The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.
Foamix Initiates Phase II Study on Acne Combination Foam
by Zacks Equity Research
Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.
Zynerba Releases Data on Epilepsy Candidate, Stock Down
by Zacks Equity Research
Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.
Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
by Zacks Equity Research
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
Generic-Drugs Stock Outlook: No Respite from Pricing Issues
by Zacks Equity Research
Generic drugmakers, in general, are having a rather poor year, primarily due to ongoing pricing pressure and rising competition.
Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead
by Ekta Bagri
Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.
Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA
by Zacks Equity Research
The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.
Falling Earnings Estimates Signal Weakness Ahead for Amphastar (AMPH)
by Zacks Equity Research
Amphastar (AMPH) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III
by Zacks Equity Research
Pharma, Inc. (EVOK) announced additional data from a phase III trial on Gimoti (nasal delivery), a novel formulation of its marketed drug, metoclopramide, for diabetic gastroparesis in adult women.
Company News for December 19, 2016
by Zacks Equity Research
Companies in the News are: NFLX,AMZN,EGLT,EVOK,JBL
3 Healthcare Stocks Poised to Beat Q2 Earnings
by Zacks Equity Research
in the second quarter, results have managed to outpace expectations so far.